The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy

Justin Greene(University of Colorado Cancer Center), John J. Arcaroli(University of Colorado Cancer Center)

Oncotarget

December 5, 2017

10.18632/oncotarget.22920

Cited by 22

Related Papers

Potent antitumor activity of cabozantinib, a c‐<scp>MET</scp> and <scp>VEGFR</scp>2 inhibitor, in a colorectal cancer patient‐derived tumor explant model

|International Journal of Cancer|2014|61

Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model

|British Journal of Cancer|2013|37